Clinical trials: sponsored by Amgen
End Stage Renal Disease, Chronic Kidney Disease
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
The primary objectives of this study are the following: 1. To demonstrate that AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with…
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Hyperphosphatemic, Kidney Disease
- Trial name
- NCT00530114
- Testing
- AMG 223
- Volunteers
- 167 people
- Sponsor
- Amgen
Anaemia, Chronic Kidney Disease (CKD)
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
To describe anaemia correction via haemoglobin measurements taken throughout observation period in ESA naive patients with chronic kidney disease initiated on darbepoetin alfa QM
- Trial name
- ADAPTATION (NCT02185911)
- Where
- 40 sites in Austria, Bulgaria and 6 more
- Volunteers
- 308 people
- Sponsor
- Amgen
Schizophrenia or Schizoaffective Disorder
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
- Trial name
- MAD (NCT02504476)
- Testing
- AMG 581, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Amgen
Unresected Stage IIIb to IVM1c Melanoma
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.
- Trial name
- NCT02147951
- Testing
- Talimogene Laherparepvec
- Where
- 24 sites in United States
- Sponsor
- Amgen
Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.
- Conditions
- Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ
- Trial name
- NCT01791374
- Testing
- Rilotumumab
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Renal Impairment
Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
The primary objective was to evaluate the incidence of clinically significant hypocalcemia following multiple 120 mg subcutaneous doses of denosumab in patients with severe chronic kidney disease (CKD) and CKD on dialysis
- Trial name
- NCT01464931
- Testing
- Denosumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Amgen
Colon Cancer, Colorectal Cancer
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer, Cancer
- Trial name
- PRECEPT (NCT00411450)
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 116 people
- Sponsor
- Amgen
Gastric Cancer
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal…
- Trial name
- RILOMET-1 (NCT01697072)
- Testing
- Rilotumumab, Epirubicin, Cisplatin
- Where
- 189 sites in United States, Australia and 25 more
- Volunteers
- 609 people
- Sponsor
- Amgen
Anaemia
Study of Haemodialysis Patients Switching From Aranesp to Biosimilar
The study will obtain data to show insight into clinical outcomes of patients switching from Darbepoetin Alfa to a epoetin alfa biosimilar.
- Trial name
- SHADE (NCT02191150)
- Where
- 23 sites in Australia, Bulgaria and 5 more
- Volunteers
- 272 people
- Sponsor
- Amgen
Psoriasis
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
Investigational drug AMG 714 will be given to 66 subjects with moderate to severe psoriasis to study safety, pharmacokinetics, and efficacy.
- Trial name
- NCT00443326
- Testing
- AMG 714
- Volunteers
- 22 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Part 1 is complete. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, phase 2 segment that will commence upon identification of the maximum tolerated dose in part 1.
- Trial name
- NCT00534027
- Testing
- AMG 655
- Volunteers
- 172 people
- Sponsor
- Amgen
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Immune Thrombocytopenic Purpura
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
Cross-sectional study, observation made by healthcare professionals of subjects or caregivers, administering romiplostim at their first standard-of-care visit 4 weeks after training with the home administration training pack.
- Trial name
- NCT02085993
- Where
- 22 sites in Austria, Belgium and 6 more
- Volunteers
- 41 people
- Sponsor
- Amgen
Diabetes Mellitus
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
- Trial name
- NCT01856881
- Testing
- AMG 876
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Locally Recurrent and Metastatic Breast Cancer
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment…
- Trial name
- NCT00511459
- Testing
- AMG 386, Bevacizumab, Paclitaxel
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Men and Women
Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects
A single-center, open-label, randomized study with a screening period of up to 21 days. Following that, eligible men and women will receive 50 mg of etanercept subcutaneously in the thigh to compare injection by auto-injection…
- Trial name
- NCT02588534
- Testing
- etanercept (ENBREL®) via auto-injector device, Etanercept (ENBREL®) via Manual injection
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia or Schizoaffective Disorder
Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body, safety and tolerability of AMG 581 in healthy participants and subjects with schizophrenia.
- Trial name
- FIH (NCT02567370)
- Testing
- AMG 581
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amgen
Solid Tumors
An Open Label Treatment Extension Study of AMG 706
This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate Amgen protocol and have been evaluated as…
- Trial name
- NCT00360867
- Testing
- AMG 706
- Volunteers
- 94 people
- Sponsor
- Amgen
Breast Neoplasms, Breast Tumors
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Tumors, Breast Cancer, Locally Recurrent and Metastatic Breast Cancer
- Trial name
- NCT00356681
- Testing
- Bevacizumab, AMG 706, Paclitaxel
- Volunteers
- 282 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.